Kedrion Biopharma and InstaLILY are set to host the Rare Connections: Healthcare AI Innovation Summit on June 3, 2026, during NY Tech Week. This exclusive, half-day event will gather leading figures from the pharmaceutical, technology, investment, and research sectors to discuss the responsible and effective implementation of artificial intelligence in healthcare.
With AI poised to revolutionize the healthcare landscape, this summit aims to unite senior executives and innovators dedicated to healthcare advancement. Attendees can expect vibrant discussions and practical case studies demonstrating how organizations are transitioning from pilot programs to large-scale AI applications that enhance operational efficiency, improve patient experiences, and foster innovation within healthcare and life sciences.
The summit will cover a wide range of topics, from cutting-edge research and clinical development to investment strategies and the ethical adoption of technology. Discussions will focus on how AI can enhance decision-making, improve patient access, and achieve better health outcomes across the healthcare ecosystem.
Prominent speakers at the event include:
- Paige Bailey, Google DeepMind - Olivia Howard, Bain Capital Private Equity - Matt Ridenour, Google DeepMind - Bob Rossilli, Kedrion Biopharma - Duccio Manetti, Kedrion Biopharma - Dmitry Simkhovich, Kedrion Biopharma - Andrea Caricasole, Kedrion Biopharma - Amit Shah, InstaLILY AI - Sumantro Das, InstaLILY AI - Crissy Costa Behrens, Insight Partners - Nithya Sabanayagam Grande, Evident Microscopy - Omer Awan, Permira - Anthony Mariello, TIAA - Peter Michel, Permira - Jason Weems, Soleo Health - Brett Dethmers, Vital Care - Tina Liu, Local Infusion - Jason Leavy, Henry Schein - Gionni Bernardini, Kedrion Biopharma - Gino Matteoni, Kedrion Biopharma
Bob Rossilli, Chief Commercial Officer of Kedrion, emphasized, “This summit underscores Kedrion's commitment to patient-focused innovation and highlights AI's potential to transform healthcare operations within our communities.” He believes that collaboration between biopharma and AI can drive significant conversations about leveraging emerging technologies within the bounds of scientific integrity and regulatory compliance.
Sumantro "Sumo" Das, Co-Founder and COO of InstaLILY, added, “Partnering with Kedrion embodies our belief that healthcare organizations embracing AI to create impact are addressing critical needs on the frontline. The Rare Connections summit offers a unique opportunity for healthcare leaders and thinkers to ignite the next phase of innovation.” Das noted that the focus is on enhancing patient outcomes and adapting to the evolving needs of healthcare organizations.
The Rare Connections: Healthcare AI Innovation Summit will take place on June 3 as part of the NY Tech Week schedule. Due to limited availability, interested individuals can join the waitlist through the provided link. For further details and a complete list of speakers and sessions, interested parties can visit the dedicated summit website.
Kedrion Biopharma specializes in producing and distributing plasma-derived therapies for rare medical conditions, employing around 5,200 staff globally with a network of numerous plasma collection centers and production facilities. The organization's mission is centered on scientific collaboration to elevate patient care through innovative solutions.
InstaLILY focuses on empowering businesses in various sectors, including healthcare and biopharma, by developing autonomous AI technologies that streamline operations and improve service delivery. Their platform integrates advanced AI capabilities to ensure efficient application across existing systems, enhancing productivity while adhering to industry regulations.
For media inquiries, please contact Jessica Fetrow at (202) 802-7119 or via email.
